T1	Disease	39 83	HER-2/neu ( HER2 ) overexpressing breast and
T2	Disease	84 103	ovarian cancers for
T3	Pharmacodynamic_phenotype	160 206	immunogenicity of a HER2 peptide vaccine based
T4	Phenotype	225 254	immune competence as assessed
T5	Chemical	292 302	antigens (
R1	treats	Arg1:T1	Arg2:T2
R2	isAssociatedWith	Arg1:T1	Arg2:T3
R3	isAssociatedWith	Arg1:T1	Arg2:T4
R4	isAssociatedWith	Arg1:T1	Arg2:T5
R5	treats	Arg1:T2	Arg2:T1
R6	isAssociatedWith	Arg1:T2	Arg2:T3
R7	isAssociatedWith	Arg1:T2	Arg2:T4
R8	isAssociatedWith	Arg1:T2	Arg2:T5
R9	influences	Arg1:T3	Arg2:T1
R10	influences	Arg1:T3	Arg2:T2
R11	influences	Arg1:T3	Arg2:T4
R12	influences	Arg1:T3	Arg2:T5
R13	influences	Arg1:T4	Arg2:T1
R14	influences	Arg1:T4	Arg2:T2
R15	isAssociatedWith	Arg1:T4	Arg2:T3
R16	influences	Arg1:T4	Arg2:T5
R17	isAssociatedWith	Arg1:T5	Arg2:T1
R18	isAssociatedWith	Arg1:T5	Arg2:T2
R19	isAssociatedWith	Arg1:T5	Arg2:T3
R20	isAssociatedWith	Arg1:T5	Arg2:T4
